静脉注射铁羧麦芽糖后出现血清类胰蛋白酶升高的过敏反应。
Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol.
作者信息
Santosh Sadashiv, Podaralla Prashanth, Miller Brent
机构信息
Renal Division, Department of Medicine , Washington University, Campus Box 8129, 660 S Euclid Ave, St. Louis, MO 63110 , USA.
出版信息
NDT Plus. 2010 Aug;3(4):341-2. doi: 10.1093/ndtplus/sfq084. Epub 2010 May 11.
Abstract
Ferumoxytol is a newly approved preparation of intravenous iron with a modified dextran shell that is thought to confer upon it a low immunogenic potential. Serious adverse reactions have been very uncommon in clinical studies, but these studies excluded patients with prior adverse reactions to other preparations of intravenous iron. Furthermore, the reactions were classified clinically. We report on a patient with a history of hypersensitivity to iron dextran who experienced an anaphylactic reaction after receiving ferumoxytol. Laboratory testing revealed an elevated serum tryptase level, confirming mast cell activation. This is the first laboratory-proven case of anaphylaxis related to ferumoxytol.
摘要
铁羧麦芽糖是一种新获批的静脉用铁制剂，其具有修饰的右旋糖酐外壳，被认为免疫原性较低。在临床研究中，严重不良反应非常罕见，但这些研究排除了既往对其他静脉用铁制剂有不良反应的患者。此外，这些反应是根据临床情况分类的。我们报告了一名对右旋糖酐铁过敏的患者，在接受铁羧麦芽糖后发生了过敏反应。实验室检测显示血清类胰蛋白酶水平升高，证实肥大细胞激活。这是首例经实验室证实与铁羧麦芽糖相关的过敏反应病例。
相似文献
1
Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol.
NDT Plus. 2010 Aug;3(4):341-2. doi: 10.1093/ndtplus/sfq084. Epub 2010 May 11.
2
Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System.
Drug Saf. 2021 Jan;44(1):107-119. doi: 10.1007/s40264-020-01022-2. Epub 2020 Nov 25.
3
Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions.
J Blood Med. 2017 Sep 26;8:155-163. doi: 10.2147/JBM.S142236. eCollection 2017.
4
Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA).
Int J Mol Sci. 2016 Jul 21;17(7):1185. doi: 10.3390/ijms17071185.
5
Risks for Anaphylaxis With Intravenous Iron Formulations : A Retrospective Cohort Study.
Ann Intern Med. 2022 May;175(5):656-664. doi: 10.7326/M21-4009. Epub 2022 Mar 29.
6
Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products.
JAMA. 2015 Nov 17;314(19):2062-8. doi: 10.1001/jama.2015.15572.
7
Ferumoxytol for the treatment of iron deficiency anemia.
Expert Rev Hematol. 2018 Oct;11(10):829-834. doi: 10.1080/17474086.2018.1518712. Epub 2018 Sep 14.
8
Serum tryptase: an indicator of anaphylaxis following fluorescein angiography.
Graefes Arch Clin Exp Ophthalmol. 1999 May;237(5):433-4. doi: 10.1007/s004170050256.
9
Elevated serum tryptase levels in a patient with protracted anaphylaxis.
Ann Allergy. 1994 Sep;73(3):232-4.
10
A case of severe anaphylactic reaction after administration of diagnostic-dose ferumoxytol in a pediatric patient.
Pediatr Radiol. 2024 Aug;54(9):1553-1555. doi: 10.1007/s00247-024-05970-0. Epub 2024 Jun 22.
引用本文的文献
1
Superparamagnetic iron oxide nanoparticles for their application in the human body: Influence of the surface.
Heliyon. 2023 May 25;9(6):e16487. doi: 10.1016/j.heliyon.2023.e16487. eCollection 2023 Jun.
2
Carboxymethyl-Dextran-Coated Superparamagnetic Iron Oxide Nanoparticles for Drug Delivery: Influence of the Coating Thickness on the Particle Properties.
Int J Mol Sci. 2022 Nov 25;23(23):14743. doi: 10.3390/ijms232314743.
3
State-of-the-Art on Biomarkers for Anaphylaxis in Obstetrics.
Life (Basel). 2021 Aug 24;11(9):870. doi: 10.3390/life11090870.
4
Multicenter Safety and Practice for Off-Label Diagnostic Use of Ferumoxytol in MRI.
Radiology. 2019 Dec;293(3):554-564. doi: 10.1148/radiol.2019190477. Epub 2019 Oct 22.
5
Lymph node imaging in initial staging of prostate cancer: An overview and update.
World J Radiol. 2017 Oct 28;9(10):389-399. doi: 10.4329/wjr.v9.i10.389.
6
A comprehensive literatures update of clinical researches of superparamagnetic resonance iron oxide nanoparticles for magnetic resonance imaging.
Quant Imaging Med Surg. 2017 Feb;7(1):88-122. doi: 10.21037/qims.2017.02.09.
7
Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA).
Int J Mol Sci. 2016 Jul 21;17(7):1185. doi: 10.3390/ijms17071185.
8
MR Angiography of Renal Transplant Vasculature with Ferumoxytol:: Comparison of High-Resolution Steady-State and First-Pass Acquisitions.
Acad Radiol. 2016 Mar;23(3):368-73. doi: 10.1016/j.acra.2015.10.021. Epub 2015 Dec 18.
9
Effect of surface charge on the colloidal stability and in vitro uptake of carboxymethyl dextran-coated iron oxide nanoparticles.
J Nanopart Res. 2013 Aug 1;15(8):1874. doi: 10.1007/s11051-013-1874-0.
10
The pharmacokinetics and pharmacodynamics of iron preparations.
Pharmaceutics. 2011 Jan 4;3(1):12-33. doi: 10.3390/pharmaceutics3010012.
本文引用的文献
1
2
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease.
Am J Hematol. 2010 May;85(5):315-9. doi: 10.1002/ajh.21656.
3
Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.
Clin J Am Soc Nephrol. 2009 Feb;4(2):386-93. doi: 10.2215/CJN.02840608. Epub 2009 Jan 28.
4
Safety of ferumoxytol in patients with anemia and CKD.
Am J Kidney Dis. 2008 Nov;52(5):907-15. doi: 10.1053/j.ajkd.2008.08.001. Epub 2008 Sep 27.
5
Clinical update: intravenous iron for anaemia.
Lancet. 2007 May 5;369(9572):1502-1504. doi: 10.1016/S0140-6736(07)60689-8.
6
Diagnostic value of tryptase in anaphylaxis and mastocytosis.
Immunol Allergy Clin North Am. 2006 Aug;26(3):451-63. doi: 10.1016/j.iac.2006.05.010.
7
Update on adverse drug events associated with parenteral iron.
Nephrol Dial Transplant. 2006 Feb;21(2):378-82. doi: 10.1093/ndt/gfi253. Epub 2005 Nov 11.
8
The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients.
Kidney Int. 2005 Oct;68(4):1801-7. doi: 10.1111/j.1523-1755.2005.00598.x.
9
Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients.
Kidney Int. 2003 Jan;63(1):217-24. doi: 10.1046/j.1523-1755.2003.00703.x.
10
Clinical use of the total dose intravenous infusion of iron dextran.
J Lab Clin Med. 1988 May;111(5):566-70.
Zotero 插件